Ethic Inc. Takes $107,000 Position in Recursion Pharmaceuticals, Inc. $RXRX

Ethic Inc. purchased a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 21,249 shares of the company’s stock, valued at approximately $107,000.

Other institutional investors have also added to or reduced their stakes in the company. ARK Investment Management LLC boosted its position in Recursion Pharmaceuticals by 7.6% during the first quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company’s stock worth $184,174,000 after purchasing an additional 2,469,104 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Recursion Pharmaceuticals by 183.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company’s stock worth $33,901,000 after purchasing an additional 4,149,346 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at about $10,118,000. Bank of New York Mellon Corp boosted its position in shares of Recursion Pharmaceuticals by 1.5% during the 1st quarter. Bank of New York Mellon Corp now owns 863,224 shares of the company’s stock valued at $4,566,000 after acquiring an additional 12,588 shares during the last quarter. Finally, Rafferty Asset Management LLC grew its holdings in shares of Recursion Pharmaceuticals by 0.5% during the first quarter. Rafferty Asset Management LLC now owns 598,420 shares of the company’s stock worth $3,166,000 after purchasing an additional 2,948 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Recursion Pharmaceuticals

In other news, insider Najat Khan sold 36,599 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $5.52, for a total transaction of $202,026.48. Following the sale, the insider directly owned 668,197 shares of the company’s stock, valued at $3,688,447.44. This represents a 5.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 8.43% of the stock is currently owned by insiders.

Recursion Pharmaceuticals Stock Down 2.3%

RXRX opened at $5.52 on Friday. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36. The company has a market capitalization of $2.40 billion, a PE ratio of -3.10 and a beta of 0.91. The firm’s 50 day simple moving average is $5.26 and its two-hundred day simple moving average is $5.22. The company has a current ratio of 3.58, a quick ratio of 3.58 and a debt-to-equity ratio of 0.02.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The firm had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The business’s revenue for the quarter was up 33.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.40) earnings per share. As a group, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on RXRX. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Wednesday, October 8th. Needham & Company LLC restated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Recursion Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $7.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.